Your browser is no longer supported. Please, upgrade your browser.
Settings
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.37 Insider Own2.80% Shs Outstand33.01M Perf Week-10.03%
Market Cap735.87M Forward P/E- EPS next Y-5.50 Insider Trans31.48% Shs Float27.64M Perf Month0.76%
Income-274.90M PEG- EPS next Q-1.45 Inst Own82.70% Short Float26.20% Perf Quarter-32.28%
Sales312.70M P/S2.35 EPS this Y23.40% Inst Trans-6.29% Short Ratio6.76 Perf Half Y-42.35%
Book/sh-5.05 P/B- EPS next Y-5.20% ROA-44.50% Target Price- Perf Year-69.47%
Cash/sh13.51 P/C1.57 EPS next 5Y-8.89% ROE267.70% 52W Range18.15 - 95.98 Perf YTD-14.29%
Dividend- P/FCF- EPS past 5Y2.70% ROI-58.70% 52W High-77.94% Beta1.59
Dividend %- Quick Ratio3.00 Sales past 5Y157.10% Gross Margin98.30% 52W Low16.64% ATR1.60
Employees498 Current Ratio3.00 Sales Q/Q16.50% Oper. Margin-73.90% RSI (14)40.85 Volatility5.46% 7.51%
OptionableYes Debt/Eq- EPS Q/Q47.20% Profit Margin-87.90% Rel Volume1.48 Prev Close22.14
ShortableYes LT Debt/Eq- EarningsFeb 25 BMO Payout- Avg Volume1.07M Price21.17
Recom2.70 SMA20-8.07% SMA50-19.27% SMA200-41.00% Volume1,588,228 Change-4.38%
Mar-12-21Upgrade H.C. Wainwright Sell → Neutral $21
Feb-23-21Downgrade H.C. Wainwright Neutral → Sell $25
Jan-15-21Downgrade BofA Securities Neutral → Underperform $40 → $27
Dec-21-20Downgrade Jefferies Buy → Hold $30
Nov-10-20Upgrade Robert W. Baird Neutral → Outperform $52
Nov-10-20Upgrade Raymond James Mkt Perform → Outperform $60
Jul-31-20Initiated Piper Sandler Overweight $82
Jul-21-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-30-20Upgrade Citigroup Neutral → Buy
Jun-30-20Downgrade UBS Buy → Neutral $135 → $57
Jun-30-20Downgrade Robert W. Baird Outperform → Neutral $52
Jun-30-20Downgrade Credit Suisse Outperform → Neutral $137 → $59
Jun-30-20Downgrade Cowen Outperform → Market Perform $47
Jun-30-20Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-29-20Downgrade Wells Fargo Overweight → Equal Weight
Jun-29-20Downgrade RBC Capital Mkts Outperform → Sector Perform $117 → $55
Jun-29-20Downgrade Oppenheimer Outperform → Perform
Jun-29-20Downgrade Goldman Buy → Neutral $150 → $60
Jun-29-20Downgrade Canaccord Genuity Buy → Hold
Jun-29-20Downgrade BMO Capital Markets Outperform → Market Perform $107 → $52
Apr-04-21 06:06AM  
Mar-27-21 11:31AM  
Mar-24-21 09:47PM  
Mar-15-21 06:06AM  
Mar-10-21 08:00AM  
Feb-26-21 12:19PM  
Feb-25-21 12:00PM  
07:00AM  
06:30AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
08:00AM  
Feb-11-21 08:00AM  
Feb-01-21 10:05PM  
Jan-27-21 01:35PM  
Jan-23-21 06:35AM  
Jan-11-21 08:00AM  
Jan-05-21 08:00AM  
Jan-04-21 12:45PM  
11:53AM  
11:45AM  
11:12AM  
09:47AM  
09:31AM  
09:15AM  
08:30AM  
06:20AM  
Jan-03-21 11:45PM  
12:10PM  
11:00AM  
10:30AM  
Jan-02-21 11:19PM  
04:00PM  
Jan-01-21 09:00PM  
07:15PM  
Dec-31-20 03:00PM  
02:12PM  
01:40PM  
12:42PM  
12:40PM  
11:45AM  
11:40AM  
Dec-30-20 02:40PM  
01:55PM  
10:30AM  
10:00AM  
10:00AM  
Dec-29-20 02:30PM  
01:15PM  
11:45AM  
11:00AM  
07:30AM  
Dec-28-20 10:28PM  
09:00PM  
08:45PM  
08:15PM  
01:20PM  
12:30PM  
12:00PM  
11:00AM  
10:20AM  
10:18AM  
Dec-26-20 03:07PM  
Dec-24-20 04:35PM  
03:56PM  
06:19AM  
Dec-23-20 09:50PM  
04:28PM  
03:00PM  
11:30AM  
11:00AM  
Dec-22-20 05:30PM  
05:00PM  
01:25PM  
12:47PM  
12:00PM  
11:30AM  
11:25AM  
06:19AM  
12:40AM  
Dec-21-20 07:35PM  
03:22PM  
01:54PM  
12:30PM  
12:00PM  
11:00AM  
06:10AM  
Dec-19-20 10:10PM  
05:58PM  
08:35AM  
Dec-18-20 04:55PM  
04:15PM  
01:20PM  
12:30PM  
12:00PM  
11:21AM  
Dec-17-20 01:35PM  
01:00PM  
12:00PM  
11:30AM  
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AKKARAJU SRINIVASDirectorMar 12Buy21.29147,0003,129,630640,688Mar 12 07:51 PM
AKKARAJU SRINIVASDirectorMar 10Buy20.9690,0001,886,622493,688Mar 12 07:51 PM
Kapadia SandipCFO and TreasurerJan 05Sale24.472,19353,66323,764Jan 05 07:01 PM
Kapadia SandipCFO and TreasurerDec 15Sale32.781,76357,79127,158Dec 16 07:00 PM
Campagna JasonChief Medical OfficerAug 18Sale47.441,19256,5438,778Aug 20 07:00 PM
Genextra S.p.A.10% OwnerAug 17Sale47.071,362,40064,123,0994,000,000Aug 17 08:13 PM
Micheli Francesco10% OwnerAug 17Sale47.071,362,40064,123,0994,000,000Aug 17 08:10 PM
Fundaro PaoloDirectorAug 17Sale47.071,362,40064,123,0994,000,000Aug 17 08:06 PM
Fundaro PaoloDirectorAug 14Sale50.5554,6002,760,1125,362,400Aug 17 08:06 PM
Micheli Francesco10% OwnerAug 14Sale50.5554,6002,760,1125,362,400Aug 17 08:10 PM
Genextra S.p.A.10% OwnerAug 14Sale50.5554,6002,760,1125,362,400Aug 17 08:13 PM
Genextra S.p.A.10% OwnerAug 13Sale52.6083,0004,365,4515,417,000Aug 17 08:13 PM
Micheli Francesco10% OwnerAug 13Sale52.6083,0004,365,4515,417,000Aug 17 08:10 PM
Fundaro PaoloDirectorAug 13Sale52.6083,0004,365,4515,417,000Aug 17 08:06 PM
Fundaro PaoloDirectorMay 13Sale84.60595,57850,385,8995,500,000May 15 05:19 PM
Micheli Francesco10% OwnerMay 13Sale84.60595,57850,385,8995,500,000May 15 04:55 PM
Genextra S.p.A.10% OwnerMay 13Sale84.60595,57850,385,8995,500,000May 15 04:46 PM
Weyer ChristianEVP, Research & DevelopmentApr 27Sale85.9518115,55717,140Apr 29 07:00 PM